About Ovid Therapeutics (NASDAQ:OVID)
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-86.05%
Return on Assets-80.34%
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics Inc (NASDAQ:OVID) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.16. View Ovid Therapeutics' Earnings History.
When will Ovid Therapeutics make its next earnings announcement?
Where is Ovid Therapeutics' stock going? Where will Ovid Therapeutics' stock price be in 2018?
4 analysts have issued 1 year target prices for Ovid Therapeutics' shares. Their predictions range from $21.00 to $26.00. On average, they expect Ovid Therapeutics' stock price to reach $23.50 in the next year. View Analyst Ratings for Ovid Therapeutics.
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include Adverum Biotechnologies (ADVM), Nightstar Therapeutics (NITE), MannKind (MNKD), BioTime (BTX), Biotie Therapies (BITI), Tyme Technologies (TYME), Circassia Pharmaceuticals (CIR), Viking Therapeutics (VKTX), Calithera Biosciences (CALA), BioSpecifics Technologies (BSTC), Cellular Biomedicine Group (CBMG), Catalyst Pharmaceuticals (CPRX), Ardelyx (ARDX), MaxCyte (MXCT), Faron Pharmaceuticals Oy (FARN), Tocagen (TOCA), Zymeworks (ZYME) and Molecular Templates (MTEM).
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Jeremy Max Levin, Chairman of the Board, Chief Executive Officer (Age 65)
- Matthew During M.D., President, Chief Scientific Officer, Director (Age 60)
- Yaron Werber M.D., Chief Business and Financial Officer, Secretary (Age 45)
- Dirk Haasner Ph.D., Senior Vice President - Global Regulatory Affairs (Age 52)
- Timothy G. Daly, Vice President - Finance, Corporate Controller (Age 45)
- Amit Rakhit M.D., Chief Medical and Portfolio Management Officer (Age 47)
- Bart Friedman, Lead Independent Director (Age 72)
- Barbara G. Duncan, Director (Age 52)
- Karen Bernstein Ph.D., Independent Director (Age 64)
- Douglas E. Williams Ph.D., Independent Director (Age 59)
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
Who owns Ovid Therapeutics stock?
Ovid Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.32%), Jennison Associates LLC (2.35%), Tekla Capital Management LLC (2.18%), Redmile Group LLC (1.27%), Sphera Funds Management LTD. (0.73%) and Schwab Charles Investment Management Inc. (0.08%). View Institutional Ownership Trends for Ovid Therapeutics.
Who sold Ovid Therapeutics stock? Who is selling Ovid Therapeutics stock?
Who bought Ovid Therapeutics stock? Who is buying Ovid Therapeutics stock?
Ovid Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Granite Point Capital Management L.P., Spark Investment Management LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Ovid Therapeutics.
How do I buy Ovid Therapeutics stock?
Shares of Ovid Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of Ovid Therapeutics stock can currently be purchased for approximately $7.03.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $173.21 million. Ovid Therapeutics employs 31 workers across the globe.
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (OVID)MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ovid Therapeutics (NASDAQ:OVID) Earnings History and Estimates Chart
Ovid Therapeutics (NASDAQ OVID) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/22/2018|| || || || || || || || |
Ovid Therapeutics (NASDAQ:OVID) Earnings Estimates
2018 EPS Consensus Estimate: ($2.19)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Ovid Therapeutics (NASDAQ:OVID)
No dividend announcements for this company have been tracked by MarketBeat.com
Ovid Therapeutics (NASDAQ OVID) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 27.52%
Ovid Therapeutics (NASDAQ OVID) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/25/2017||Jeremy M Levin||CEO||Buy||15,334||$7.15||$109,638.10||4,601,529|| |
Ovid Therapeutics (NASDAQ OVID) News Headlines
Ovid Therapeutics (NASDAQ:OVID) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ovid Therapeutics (NASDAQ:OVID) Income Statement, Balance Sheet and Cash Flow Statement
Ovid Therapeutics (NASDAQ OVID) Stock Chart for Wednesday, February, 21, 2018